ArticleJournal of cancer research and clinical oncology2022
Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma.
Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06284356 (Pan Immune Inflammation Value for Determining Perioperative Complications of Laparoscopic Sleeve Gastrectomy), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pan Immune Inflammation Value for Determining Perioperative Complications of Laparoscopic Sleeve Gastrectomy: A Prospective Cohort Study
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Prognostic significance of the pretreatment pan-immune-inflammation value in cancer patients: an updated meta-analysis of 30 studies.Frontiers in nutrition · 2023Pooled it
- Preoperative pan-immune-inflammation value and geriatric nutritional risk index predict outcomes of elderly patients with endometrial carcinoma after radical surgery.BMC women's health · 2026Article
- The potential role of pan-immune-inflammation value in differentiating pediatric osteomyelitis from soft tissue infections.Translational pediatrics · 2026Article
- Predictors of response and survival in cemiplimab-treated cutaneous squamous cell carcinoma: multicenter real-world evidence from Germany.Journal of cancer research and clinical oncology · 2026Article
- Immunohistochemical Characterisation of the Interstitial Inflammatory Environment: T-Cell- and B-Cell-Dominant Subtypes of Hidradenitis Suppurativa.Dermatopathology (Basel, Switzerland) · 2025Article
- Association of pan-immune-inflammatory value with metabolic dysfunction-associated steatotic liver disease: findings from NHANES 2017-2020.BMC gastroenterology · 2025Article
- Pan-immune-inflammation value predicts survival in inflammatory breast cancer patients.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Pan-immune-inflammation value and its association with all-cause and cause-specific mortality in the general population: a nationwide cohort study.Frontiers in endocrinology · 2025Article
- Pan-immune-inflammation value: a new prognostic index in epithelial ovarian cancer.BMC cancer · 2024Article
- Article
- Review
- Introducing MCC-PS: a novel prognostic score for Merkel cell carcinoma.Frontiers in oncology · 2024Article
- Novel pretreatment nomograms based on pan-immune-inflammation value for predicting clinical outcome in patients with head and neck squamous cell carcinoma.Frontiers in oncology · 2024Article
- High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.Discover oncology · 2023Article
- Pan-immune-inflammation value is associated with poor prognosis in patients undergoing peritoneal dialysis.Renal failure · 2023Article
- Model for End-Stage Liver Disease Correlates with Disease Relapse and Death of Patients with Merkel Cell Carcinoma.Cancers · 2023Article
- Article
- Prognostic value of pan-immune-inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single-center retrospective study.Contemporary oncology (Poznan, Poland) · 2023Article
- Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy.Journal of inflammation research · 2023Article
- The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.Journal of cancer research and clinical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to determine whether the pan-immune-inflammation value (PIV) of patients with Merkel cell carcinoma (MCC) at primary diagnosis differs from controls and whether it is associated with disease stage and outcome.
methodsIn this retrospective study, we recruited MCC patients with stage I-III. PIV was calculated from absolute complete blood cell counts obtained within one week at MCC diagnosis as follows: [neutrophils (10
resultsThe median PIV in MCC patients was significantly increased compared to both CM patients as well as healthy controls. PIV of MCC patients in stage II and III was significantly higher compared to stage I patients. ROC analysis revealed that MCC recurrence was significantly associated with a PIV greater than 372 [p < 0.0001, Youden index 0.58; hazard ratio: 4 (95% confidence interval: 1.7 to 9.2)]. In multivariate analysis, only a PIV greater than 372 and higher MCC stage were determined as independent predictors for disease recurrence.
conclusionWe determined, for the first time, the prognostic ability of the promising blood-based biomarker PIV in MCC patients and observed that PIV is increased in MCC patients in dependence on disease stage and independently predicts MCC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.